Key result
Third and fourth generations of dihydropyridine calcium channel blockers effectively lower blood pressure without causing baroreflex activation and provide target organ protection.
This review discusses the pharmacological mechanisms underlying the clinical efficacy of third and fourth-generation dihydropyridine calcium channel blockers for hypertension.
Answers are grounded in this paper and cite their sources.
Newer dihydropyridine CCBs may warrant consideration in hypertension; review extends mechanistic insights but leaves outcome trials open.
Since the calcium channel blocker (CCB) has become one of the most prescribed agents for antihypertensive monotherapy in the world, this brief review will focus on the recent research and development of the dihydropyridine (DHP) CCB, addressing pharmacological mechanisms for the clinical efficacy of the third and fourth generations of the DHP CCBs, especially on their possible central mechanisms underlying lowering blood pressure.
No takes yet. Share an insight, caveat, or question.
Iadecola et al. (2017) conducted a review in Hypertension. Dihydropyridine calcium channel blockers was evaluated. Third and fourth generations of dihydropyridine calcium channel blockers effectively lower blood pressure without causing baroreflex activation and provide target organ protection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: